• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Abivax

    Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax presents first-half 2024 financial results
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax Provides Operational and Key Program Update
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting
    From Abivax
    Via GlobeNewswire
    Tickers ABVX
    Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
    From Abivax
    Via GlobeNewswire
    Abivax annual ordinary and extraordinary general meeting of May 30, 2024 - Availability of the preparatory documents
    From Abivax
    Via GlobeNewswire
    Abivax publishes financial reports with the French and U.S. securities regulatory agencies
    From Abivax
    Via GlobeNewswire
    Abivax reports 2023 financial results and operational update
    From Abivax
    Via GlobeNewswire
    Abivax appoints Ana Sharma as Vice President, Global Head of Quality
    From Abivax
    Via GlobeNewswire
    Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease
    From Abivax
    Via GlobeNewswire
    Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
    From Abivax
    Via GlobeNewswire
    Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
    From Abivax
    Via GlobeNewswire
    Abivax 2024 Financial Communication Calendar
    From Abivax
    Via GlobeNewswire
    Abivax announces the resumption of its liquidity contract
    From Abivax
    Via GlobeNewswire
    Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
    From Abivax
    Via GlobeNewswire
    Abivax Releases the Results of its June 9, 2022 Ordinary Annual and Extraordinary General Meeting
    From ABIVAX
    Via AccessWire
    Abivax Phase 2a Study Results of Obefazimod (ABX464) in Rheumatoid Arthritis Published in the Journal "Annals of the Rheumatic Diseases" and Selected for Presentation at EULAR 2022
    From ABIVAX
    Via AccessWire
    Abivax Announces Annual Ordinary and Extraordinary General Meeting on June 9, 2022, and the Availability of the Preparatory Documents
    From ABIVAX
    Via AccessWire
    Abivax Publishes Universal Registration Document 2022 'Document d'Enregistrement Universel'
    From ABIVAX
    Via AccessWire
    Abivax Reports Excellent One-Year Efficacy and Safety Data of ABX464 Phase 2b Maintenance Trial in Ulcerative Colitis
    From ABIVAX
    Via AccessWire
    Abivax Reports 2021 Financial Results and Operations Update
    From ABIVAX
    Via AccessWire
    Abivax Reports Promising ABX464 Phase 2a One-Year Maintenance Results in Rheumatoid Arthritis
    From ABIVAX
    Via AccessWire
    Abivax to host Satellite Symposium at the 17th Congress of ECCO on Feb. 17, 2022
    From ABIVAX
    Via AccessWire
    Abivax 2022 Financial Communication Calendar
    From ABIVAX
    Via AccessWire
    Abivax's Phase 1/2 Clinical Study Results of ABX196 in Liver Cancer to be Presented on Jan. 21, at ASCO GI Cancers Symposium 2022
    From ABIVAX
    Via AccessWire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.